Cite
MLA Citation
Paolo A Ascierto et al.. “Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.” Lancet oncology, vol. 24, no. 1, 2023, pp. 33–44. http://access.bl.uk/ark:/81055/vdc_100173693529.0x000017